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Abstract
An asymmetric decarboxylative Csp3–Csp2 cross-coupling has been achieved via the synergistic 
merger of photoredox and nickel catalysis. This mild, operationally simple protocol transforms a 
wide variety of naturally abundant α-amino acids and readily available aryl halides into valuable 
chiral benzylic amines in high enantiomeric excess, thereby producing motifs found in 
pharmacologically active agents.
Nickel catalysis has provided numerous pathways to forge carbon–carbon bonds via a 
variety of well-known coupling protocols (e.g., Negishi, Suzuki–Miyaura, Stille, Kumada, 
and Hiyama couplings).1 The value of these transformations lies in their capacity to effect 
useful fragment couplings with broad functional-group tolerance, which enables a highly 
modular, building-block approach to the construction of complex organic molecules. 
Beginning in 2005, one of our laboratories has demonstrated that chiral nickel catalysts can 
be employed to achieve the enantioselective coupling of a broad spectrum of racemic alkyl 
halides (e.g., α-halocarbonyl compounds, as well as benzylic, allylic, and unactivated alkyl 
halides) with a wide array of common organometallic nucleophiles (e.g., organozinc, -boron, 
-silicon, -magnesium, and -zirconium reagents; Scheme 1A).2 A prominent feature of this 
approach is the capacity to employ racemic Csp3–halide containing starting materials to 
forge Csp3–Csp3 and Csp3–Csp2 bonds with high levels of stereocontrol in the 
enantioconvergent fragment-coupling step.
Visible-light-mediated photoredox catalysis has emerged in recent years as a valuable 
concept in organic synthesis wherein single-electron transfer (SET) events with organic 
substrates are facilitated.3 This general strategy allows for the development of bond 
constructions that are often elusive or currently impossible via classical two-electron 
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pathways.4 Recently, one of our laboratories introduced a dual photoredox–nickel catalysis 
platform that enables carboxylate oxidation–CO2 extrusion as a generic mechanism for 
nucleophile activation, a development that allows carboxylic acids to be used in lieu of 
organometallic nucleophiles (e.g., organoboron or organozinc reagents) in nickel-mediated 
fragment couplings (Scheme 1B).5,6 This strategy has subsequently enabled the catalytic 
decarboxylative functionalization of a wide range of Csp3 centers with aryl, heteroaryl, and 
vinyl fragments using abundant, inexpensive, yet structurally complex carboxylic acids (e.g., 
α-amino acids, carbohydrates, and α-oxy acids).7
In view of the appealing attributes of (i) enantioconvergent nickel-catalyzed cross-coupling 
and (ii) metallaphotoredox-mediated decarboxylative arylation, we recently decided to 
pursue the possibility that the two technologies could be merged to enable the 
enantioselective synthesis of benzylic amines from readily available α-amino acid starting 
materials. Because benzylic amines are a subunit in a wide array of bioactive compounds, 
including agrochemicals, natural products, and pharmaceuticals (e.g., rivastigmine for 
Alzheimer's disease and repaglinide for type II diabetes),8,9 the development of 
enantioselective methods for the synthesis of this important pharmacophore from 
inexpensive starting materials remains an important challenge.10 In this communication, we 
report the successful merger of enantioselective nickel-catalyzed cross-coupling with 
metallaphotoredox-mediated decarboxylative arylation, specifically, the first example of a 
one-step synthesis of enantioenriched benzylic amines from a wide array of naturally 
occurring α-amino acids using light and a synergistic combination of an iridium 
photocatalyst and a chiral nickel complex.
Design Plan
Based on our previous investigation of the decarboxylative arylation of α-amino acids, we 
envisioned that an enantioselective variant would be accessible via an analogous 
mechanism.5 Thus, photocatalyst-mediated oxidation and decarboxylation of an α-amino 
acid would produce a prochiral α-amino radical (Scheme 1C).5,7,11 Meanwhile, activation of 
an aryl halide via oxidative addition would lead to a Ni(II)–aryl complex, which would 
intercept the newly generated α-amino radical. The resulting diorganonickel(III) adduct 
would then undergo reductive elimination to forge the desired Csp3–Csp2 bond. The presence 
of an appropriate chiral ligand would induce enantioselectivity.
Results
Our investigation into synergistic photoredox- and nickel-catalyzed asymmetric 
decarboxylative arylation began with the evaluation of several ligand classes for the coupling 
of N-Boc-leucine with 4-bromobenzonitrile. We were intrigued to determine that chiral 1,2-
diamine and bis(oxazoline) ligands, which have found extensive use in related asymmetric 
nickelcatalyzed cross-coupling reactions that employ organometallic nucleophiles as 
coupling partners, were ineffective for this enantioselective decarboxylative arylation (Table 
1, entries 1 and 2).12,13 In contrast, semicorrin-like ligand 4 delivered the desired product 
with promising ee, although modest yield (entry 3).14 Whereas the addition of a tert-butyl 
substituent in the meta positions of ligand 4 was beneficial (ligand 5; entry 4), the 
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incorporation of a tert-butyl substituent in the para positions provided even higher 
enantioselectivity and yield (ligand 6; entry 5). From a practical point of view, it is worth 
noting that ligand (S,S)-6 is commercially available and air-stable.15
A series of control experiments established that the nickel complex, the chiral ligand, the 
photocatalyst, and light are all essential (entries 6–9). Consistent with our hypothesis that the 
reaction proceeds through a radical intermediate (Scheme 1C), the choice of either (S,S)-6 or 
(R,R)-6 as the chiral ligand leads to the formation of opposite enantiomers of the desired 
product from enantiopure Boc-L-Leu-OH, with the stereo-chemical outcome determined 
entirely by the configuration of the ligand (entry 5 versus entry 10).
With optimized reaction conditions in hand, we next evaluated the scope of α-amino acids 
that can be employed in this asymmetric arylation reaction. As illustrated in Table 2, a 
variety of N-Boc-protected α-amino acids that bear an alkyl side chain (e.g., protected Leu, 
Ser, Asp, Glu, and Lys) were arylated with good to excellent enantioselectivity (entries 1 and 
3–8; 71–84% yield, 82–92% ee).16 Although these conditions were optimized for N-Boc-
protected α-amino acids, they can also be applied to an N-Cbz-protected substrate, albeit in 
more modest yield (entry 2; 45% yield, 88% ee). In the case of α-amino acids that bear a 
CH2Ar (Ar = aromatic) side chain, ligand 5 proved to be optimal (entries 9–12; 51–76% 
yield, 84–91% ee). The mild nature of this protocol allows for the presence of a wide range 
of functional groups, including carbamate, ether, ester, alkyl chloride, carbonate, indole, and 
thiophene moieties.
We next turned our attention to determining the scope of aromatic halides that are amenable 
to cross-coupling under the optimized reaction conditions. As illustrated in Table 3, in the 
case of α-amino acids that bear an alkyl side chain, a range of aryl halides can be 
incorporated with good efficiency and high ee, including substituted pyridyl groups, which 
are commonly found in pharmaceutically relevant compounds (entries 1–8; 46–76% yield, 
88–92% ee). Using ligand 5, N-Boc-protected phenylalanine can be cross-coupled with aryl 
and heteroaryl halides in moderate-to-good yield and with high enantioselectivity (entries 9–
12; 47–84% yield, 90–93% ee). When an electron-neutral aryl halide (Ph–I) was employed 
as a coupling partner with N-Boc-protected phenylalanine, the desired benzylic amine was 
generated with more modest ee (66%) and comparable yield (64%).
To highlight the utility of this asymmetric cross-coupling reaction, we applied our protocol 
to the synthesis of the cores of pharmacologically active molecules. Using the conditions 
outlined in Table 2, N-Boc-leucine was successfully cross-coupled to provide protected 
benzylic amines 717 and 818 in good yield and excellent enantioselectivity (Scheme 2). 
Products 7, bearing bis-trifluoromethylphenyl substitution, and 8, bearing a methylbenzoate 
group, could be advanced to the corresponding bioactive compounds through 
straightforward synthetic sequences (e.g., amide coupling and Buchwald–Hartwig 
amination).
In conclusion, we have developed an enantioselective decarboxylative Csp3–Csp2 cross-
coupling reaction of α-amino acids with aryl halides by interfacing photoredox and nickel 
catalysis. This enantioconvergent approach provides ready access to enantioenriched 
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benzylic amine products using abundant feedstock α-amino acids as coupling partners in 
place of traditional organometallic nucleophiles. The generality of this protocol has been 
illustrated through the cross-coupling of a variety of amino acids and aryl halides. Finally, 
we have demonstrated the utility of this strategy for the preparation of pharmaceutically 
relevant compounds.
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Scheme 1. Asymmetric Decarboxylative Arylation of α-Amino Acids
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Scheme 2. Catalytic Asymmetric Coupling To Produce Pharmacophores
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Table 1
Catalytic Enantioselective Decarboxylative Arylationa
entry variation from standard conditions ee (%) yield (%)b
1 (S,S)-2 instead of (S,S)-6 – <2
2 (S,S)-3 instead of (S,S)-6 9 28
3 (S,S)-4 instead of (S,S)-6 77 34
4 (S,S)-5 instead of (S,S)-6 86 59
5 none 92 69
6 no NiCl2·glyme – <2
7 no (S,S)-6 – <2
8 no photocat. 1 – 0
9 no light – 0
10 (R,R)-6 instead of (S,S)-6 −91 72
aAll data are the average of two experiments.
b
Yields determined by 1H NMR spectroscopy using 1,3-bis(trifluoromethyl)-5-bromobenzene as an internal standard.
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Table 2
Scope of the α-Amino Acida
entry product entry product
1 2
3 4
5 6
7 8
9 10
11 12
aAll data are the average of two experiments.
b
Reaction performed using 5 mol% NiCl2·glyme and 5.5 mol% (S,S)-6.
c
Reaction performed using 2.2 mol% (S,S)-5, without 10 mol% TBAI (see the Supporting Information).
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Table 3
Scope of the Aryl Halidea
entry product entry product
1 2
3 4
5 6
7 8
9 10
11 12
aAll data are the average of two experiments.
b
Reaction performed using an aryl iodide.
c
The cross-coupling product was cyclized to form a pyrrolidine.
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d
Reaction performed using 2.2 mol% (S,S)-5, without 10 mol% TBAI (see the Supporting Information).
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